☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Neurofibromatosis Type 1
AstraZeneca and MSD's Koselugo (selumetinib) Receive the EU's Approval for Neurofibromatosis Type 1 and Plexiform Neurofibromas
June 22, 2021
AstraZeneca and MSD's Selumetinib Receive MHLW's Orphan Drug Designation for Neurofibromatosis Type 1 in Japan
June 30, 2020
AstraZeneca and MSD Report FDA's Acceptance of NDA for Selumetinib in Patients with Neurofibromatosis Type 1
November 15, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
